You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Specgx Llc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for SPECGX LLC, and what generic alternatives to SPECGX LLC drugs are available?

SPECGX LLC has sixty-one approved drugs.

There is one US patent protecting SPECGX LLC drugs.

There are ten patent family members on SPECGX LLC drugs in nine countries and thirty supplementary protection certificates in ten countries.

Summary for Specgx Llc
International Patents:10
US Patents:1
Tradenames:47
Ingredients:31
NDAs:61
Drug Master File Entries: 73

Drugs and US Patents for Specgx Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Specgx Llc ACETAMINOPHEN AND CODEINE PHOSPHATE acetaminophen; codeine phosphate TABLET;ORAL 040419-002 May 31, 2001 AA RX No Yes ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc LISDEXAMFETAMINE DIMESYLATE lisdexamfetamine dimesylate CAPSULE;ORAL 211840-006 Aug 25, 2023 AB RX No No ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc MORPHINE SULFATE morphine sulfate TABLET, EXTENDED RELEASE;ORAL 076412-003 Jul 31, 2003 AB RX No No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Specgx Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Specgx Llc EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217-004 Aug 24, 2012 5,914,131 ⤷  Try a Trial
Specgx Llc EXALGO hydromorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 021217-002 Mar 1, 2010 5,914,131 ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-001 Approved Prior to Jan 1, 1982 3,922,305 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for SPECGX LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 5 mg/5 mL and 10 mg/5 mL ➤ Subscribe 2010-04-13

Supplementary Protection Certificates for Specgx Llc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2316456 SPC/GB17/078 United Kingdom ⤷  Try a Trial PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE.; REGISTERED: UK EU/1/14/988 20150330; UK PLGB 50742/0001 20150330
1644019 301019 Netherlands ⤷  Try a Trial PRODUCT NAME: LISDEXAMFETAMINE, DESGEWENST IN DE VORM VAN EEN MESYLAAT- OF HYDROCHLORIDEZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 124498 20190528; FIRST REGISTRATION: GB PL 08081/0050-52 20130201
1644019 LUC00189 Luxembourg ⤷  Try a Trial PRODUCT NAME: LISDEXAMFETAMINE, OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; AUTHORISATION NUMBER AND DATE: PL08081/0050-52 20200901
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.